| A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer (NCT07462143) | RemeGen Co., Ltd. | 2026-05-12 |
| A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC288 in the Treatment of Solid Tumors (NCT07537881) | RemeGen Co., Ltd. | 2026-04-30 |
| Phase III Clinical Trial of Telitacicept Injection in the Treatment of Patients With Connective Tissue Disease-related Interstitial Lung Disease (NCT07495033) | RemeGen Co., Ltd. | 2026-04-20 |
| RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC) (NCT07416474) | RemeGen Co., Ltd. | 2026-04-03 |
| A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG) (NCT07249632) | RemeGen Co., Ltd. | 2026-01-13 |
| A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. (NCT07315750) | RemeGen Co., Ltd. | 2026-01-01 |
| A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid Tumors (NCT07105215) | RemeGen Co., Ltd. | 2025-08-11 |
| A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC (NCT06962865) | RemeGen Co., Ltd. | 2025-06-30 |
| A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (NCT06944496) | RemeGen Co., Ltd. | 2025-05-15 |
| A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC (NCT06883630) | RemeGen Co., Ltd. | 2025-03-13 |
| Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer (NCT06642545) | RemeGen Co., Ltd. | 2025-02-10 |
| Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer (NCT06105008) | RemeGen Co., Ltd. | 2024-12-20 |
| A Single Dose Study to Investigate the Pharmacokinetics (PK) of Telitacicept Pre-filled Injection and Freeze-dried Powder Injection in Chinese Healthy Subjects (NCT06549959) | RemeGen Co., Ltd. | 2024-08-05 |
| To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2 (NCT06378242) | RemeGen Co., Ltd. | 2024-06-14 |
| Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer (NCT06227156) | RemeGen Co., Ltd. | 2024-04-08 |
| A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation (NCT05745740) | RemeGen Co., Ltd. | 2024-04-01 |
| DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy (NCT06221748) | RemeGen Co., Ltd. | 2024-02-22 |
| RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer (NCT06173037) | RemeGen Co., Ltd. | 2024-01-19 |
| A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer (NCT06155396) | RemeGen Co., Ltd. | 2024-01-11 |
| DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer (NCT06178159) | RemeGen Co., Ltd. | 2023-11-28 |
| Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma. (NCT06155383) | RemeGen Co., Ltd. | 2023-11-27 |
| A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors (NCT06016062) | RemeGen Co., Ltd. | 2023-09-14 |
| RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC (NCT05821933) | RemeGen Co., Ltd. | 2023-09-07 |
| A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer (NCT05980481) | RemeGen Co., Ltd. | 2023-08-04 |
| A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors (NCT06038396) | RemeGen Co., Ltd. | 2023-08-03 |
| Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer (NCT06227117) | RemeGen Co., Ltd. | 2023-07-27 |
| A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours (NCT05804526) | RemeGen Co., Ltd. | 2023-07-19 |
| RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression (NCT05940896) | RemeGen Co., Ltd. | 2023-06-29 |
| RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects (NCT05943379) | RemeGen Co., Ltd. | 2023-06-08 |
| Efficacy and Safety of RC28-E Versus Aflibercept in Diabetic Macular Edema (NCT05885503) | RemeGen Co., Ltd. | 2023-06-08 |
| A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors (NCT05867303) | RemeGen Co., Ltd. | 2023-06-05 |
| A Study of Telitacicept in Subjects With Childhood-onset Systemic Lupus Erythematosus (NCT05687526) | RemeGen Co., Ltd. | 2023-05-25 |
| A Study of Telitacicept for IgA Nephropathy (TELIGAN) (NCT05799287) | RemeGen Co., Ltd. | 2023-04-28 |
| A Study of Telitacicept in Lupus Nephritis (NCT05680480) | RemeGen Co., Ltd. | 2023-04-17 |
| A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's Syndrome (NCT05673993) | RemeGen Co., Ltd. | 2023-04-06 |
| Study of Telitacicept in Generalized Myasthenia Gravis (NCT05737160) | RemeGen Co., Ltd. | 2023-03-28 |
| Efficacy and Safety of RC28-E Versus Aflibercept (NCT05727397) | RemeGen Co., Ltd. | 2023-03-14 |
| A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid Tumours (NCT05508334) | RemeGen Co., Ltd. | 2023-01-30 |
| A Study of RC108-ADC in Subjects With Advanced Digestive System Malignant Tumor (NCT05628857) | RemeGen Co., Ltd. | 2022-11-11 |
| To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG) (NCT05514158) | RemeGen Co., Ltd. | 2022-09-28 |
| A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma (NCT05302284) | RemeGen Co., Ltd. | 2022-06-14 |
| A Study of RC48-ADC Combined With JS001 For Perioperative Treatment of Muscle-Invasive Bladder Cancer (NCT05297552) | RemeGen Co., Ltd. | 2022-05-26 |
| Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus (NCT05247203) | RemeGen Co., Ltd. | 2022-05-11 |
| A Study of RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression) (NCT05135715) | RemeGen Co., Ltd. | 2022-04-19 |
| A Study of RC48-ADC for the Treatment of HER2-expressing Gynecological Malignancies (NCT04965519) | RemeGen Co., Ltd. | 2021-12-21 |
| A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours (NCT04914117) | RemeGen Co., Ltd. | 2021-11-29 |
| A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy (NCT04905212) | RemeGen Co., Ltd. | 2021-11-04 |
| A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression (NCT04714190) | RemeGen Co., Ltd. | 2021-03-24 |
| Evaluation of RC28-E Injection in Diabetic Macular Edema (NCT04782115) | RemeGen Co., Ltd. | 2021-03-17 |
| A Study of RC108-ADC in Subjects With Advanced Malignant Solid Tumors (NCT04617314) | RemeGen Co., Ltd. | 2021-03-10 |
| A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2 (NCT04400695) | RemeGen Co., Ltd. | 2020-09-29 |
| A Study of RC48-ADC in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer (NCT04329429) | RemeGen Co., Ltd. | 2020-08-24 |
| A Study of TACI（Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor）-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia Gravis (NCT04302103) | RemeGen Co., Ltd. | 2020-07-07 |
| A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors (NCT04175847) | RemeGen Co., Ltd. | 2020-04-14 |
| A Study of RC18 Administered Subcutaneously to Subjects With Primary IgA(Immunoglobulin A) Nephropathy (NCT04291781) | RemeGen Co., Ltd. | 2020-04-13 |
| A Study of RC98 in Subjects With Advanced Malignant Solid Tumors (NCT04190823) | RemeGen Co., Ltd. | 2020-03-15 |
| A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's Syndrome (NCT04078386) | RemeGen Co., Ltd. | 2019-11-21 |
| Study of Recombinant Human B Lymphocyte(RC18) Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE) (NCT04082416) | RemeGen Co., Ltd. | 2019-10-16 |
| A Phase I Study of TACI-antibody Fusion Protein Injection (RC18) in Healthy Adult Chinese Subjects (NCT04235933) | RemeGen Co., Ltd. | 2019-09-17 |
| A Study of RC48-ADC in Subjects With HER2-negative Locally Advanced or Metastatic Urothelial Cancer (NCT04073602) | RemeGen Co., Ltd. | 2019-08-19 |
| A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer (NCT03809013) | RemeGen Co., Ltd. | 2019-01-07 |
| Evaluation the Pharmacokinetics,Safety,Tolerability of Single Intravitreal Injection RC28-E in Subjects With Wet Age-Related Macular Degeneration (NCT03777254) | RemeGen Co., Ltd. | 2019-01-07 |
| A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer (NCT04311034) | RemeGen Co., Ltd. | 2018-09-26 |
| A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer Subjects With the Overexpression of HER2 (NCT03556345) | RemeGen Co., Ltd. | 2018-07-10 |
| A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases (NCT03500380) | RemeGen Co., Ltd. | 2018-04-24 |
| A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders (NCT03330418) | RemeGen Co., Ltd. | 2018-01-29 |
| A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer (NCT03507166) | RemeGen Co., Ltd. | 2017-12-28 |